|By Marketwired .||
|March 20, 2014 10:35 AM EDT||
NEW YORK, NY -- (Marketwired) -- 03/20/14 -- A new prostate cancer study demonstrated that robotic prostate surgery produces fewer positive surgical margins and requires less use of additional cancer therapy within two years of the surgery.
In a UCLA-lead comparative review of robotic prostate surgery verses open surgery, the findings indicated that robotic surgery reduces the risk of positive surgical margins by 5 percent and also reduces the need for secondary prostate cancer treatment. David B. Samadi, MD, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital, believes these findings have widespread implications.
"We continue to see evidence of robotic surgery success being amplified in the hands of experienced surgeons," Dr. Samadi said. Using his own enhanced procedure, the Samadi Modified Advanced Robotic Technique (SMART), he has successfully performed 5,600 robotic radical prostatectomies. "Successful and thorough removal of cancerous tissue depends on a variety of factors: the dexterity of robotic tools, a bloodless surgical field, and most importantly, a highly skilled and experienced surgeon," he said.
After surgery, the removed prostate tissue is assessed on the volume of cancer cells in the margins. A positive surgical margin indicates that some prostate cancer may remain in the body, thereby increasing the chances of metastasis or recurrence. Surgical margin results are often used to determine whether secondary treatment, such as radiation or hormone therapy, is necessary.
In this study, positive surgical margins were present in 13.6 percent of the 5,556 robotic surgery patients and 18.3 percent of the 7,878 open surgery patients. "Clean surgical margins mean a lower chance of disease recurrence, and may subsequently mean less follow-up care and fewer healthcare expenses. Collectively, the short- and long-term benefits of robotic prostate surgery are tremendous," stated Dr. Samadi.
The study findings appear online in European Urology, http://www.europeanurology.com/article/S0302-2838%2814%2900134-1/abstract/comparative-effectiveness-of-robot-assisted-versus-open-radical-prostatectomy-cancer-control
Dr. Samadi is internationally recognized for robotic surgery excellence. He performs SMART robotic prostate removal surgery at The Lenox Hill Hospital Prostate Cancer Center in New York City.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2547297
David B. Samadi, M.D
Chairman of Urology
Chief of Robotic Surgery at Lenox Hill Hospital
485 Madison Avenue
New York, NY 10022